Related Experiment Video
Updated: Jun 8, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
Natural history of tako-tsubo cardiomyopathy
Guido Parodi1, Benedetta Bellandi1, Stefano Del Pace1
1Department of Cardiology, Careggi Hospital, University of Florence, Florence, Italy.
Insights
Tako-tsubo cardiomyopathy (TTC) rarely recurs, but many patients experience symptoms like chest pain or dyspnea, leading to hospital readmissions. Long-term mortality is elevated, influenced by comorbidities rather than initial heart dysfunction severity.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Research
Background:
- Tako-tsubo cardiomyopathy (TTC), or stress-induced cardiomyopathy, is an acute cardiac syndrome with transient left ventricular (LV) dysfunction.
- The exact cause and long-term prognosis of TTC remain incompletely understood.
Purpose of the Study:
- To evaluate the long-term outcomes of patients diagnosed with TTC.
- To identify predictors of mortality and clinical events in TTC patients.
Main Methods:
- Prospective study of 116 consecutive patients with TTC.
- Long-term follow-up assessing death, TTC recurrence, and hospitalizations.
- Comparison of TTC patient mortality with age- and sex-matched general population using standardized mortality ratio (SMR).
Main Results:
- Most patients (55%) remained symptomatic at 2.0 ± 1.3 years follow-up.
- High rehospitalization rate (25%) primarily for chest pain and dyspnea.
- Overall mortality was higher than the general population (SMR = 3.40).
- Charlson comorbidity index, not initial LV dysfunction, predicted long-term mortality.
Conclusions:
- TTC recurrence is uncommon, but symptomatic events like chest pain and dyspnea are frequent, causing readmissions.
- Long-term mortality in TTC patients is significantly higher than in the general population.
- Comorbidities, rather than the severity of initial LV dysfunction, are key determinants of long-term outcomes in TTC.
Background:
Stress-induced or tako-tsubo cardiomyopathy (TTC) is a rare acute cardiac syndrome characterized by transient left ventricular (LV) dysfunction of uncertain cause and outcome. This study sought to assess the long-term outcome of patients with TTC.
Methods:
One-hundred sixteen consecutive patients were prospectively included in the study and observed at long-term follow-up. Primary end points were death, TTC recurrence, and hospitalization from any cause.
Results:
Mean initial LV ejection fraction (LVEF) at admission was 36% ± 9%. Two patients died of refractory heart failure during hospitalization. Of the patients who were discharged alive all except one showed complete LV functional recovery. At follow-up (2.0 ± 1.3 years), only 64 (55%) patients were asymptomatic. Rehospitalization rate was high (25%), with chest pain (n = 6) and dyspnea (n = 5) as the most common causes. Only two patients had a recurrence of TTC. Eleven patients died (seven from cardiovascular cause). There was no significant difference in mortality (12% vs 7%; P = .284) and in the other clinical events between patients with and without severe LV dysfunction at presentation (LVEF ≤ 35%). Mortality observed in patients with TTC was compared with age and sex-specific mortality of the general population using the standardized mortality ratio (SMR) method. The SMR was 3.40 (95% CI, 1.83-6.34) in the TTC population. The only independent predictor of death at Cox analysis was Charlson comorbidity index (hazard ratio, 1.786; P = .0001), but the degree of initial LV dysfunction was not an independent predictor of death.
Conclusions:
The recurrence of TTC is rare, but recurrences of chest pain or dyspnea are common in patients with TTC and frequently lead to hospital readmission. Long-term mortality is higher as compared with the control general population and at least in part related to patients' comorbidities. Initial LV dysfunction severity does not seem to impact long-term event rates.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Coronary Artery Disease II: Pathophysiology
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis I: Introduction
